<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404076</url>
  </required_header>
  <id_info>
    <org_study_id>GIST m3</org_study_id>
    <nct_id>NCT03404076</nct_id>
  </id_info>
  <brief_title>Unifying Advanced Treatment With Advanced Imaging</brief_title>
  <acronym>GISTm3</acronym>
  <official_title>Optimized Response Assessment of Gastrointestinal Stromal Tumors Using Dual-Energy CT: Prospective Multicenter-Multinational Trial in Patients Undergoing Targeted Therapy With a TKI Inhibitor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Clinical Radiology and Nuclear Medicine Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Siemens Healthcare Diagnostics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates response assessment of gastrointestinal stromal tumors using Dual
      Energy CT (DECT) in patients undergoing targeted therapy with a TKI Inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients treated with targeted therapies by tyrosine kinase inhibition (TKI) almost always
      show different response patterns than tumors treated with cytotoxic chemotherapy. Tumor
      manifestations treated with targeted therapies often show only minor measurable changes in
      tumor size despite inhibition of tumor proliferation. Decrease in tumor size fulfilling the
      criteria of a partial remission according to RECIST may occur at a delayed stage of treatment
      after several months (PMID 19620483). Sometimes, even an initial increase of maximum tumor
      diameters may be observed although those patients are treatment responders with respect to
      'hard' study endpoints like overall survival or progression free survival. As a result,
      patients often are misclassified too early as non-responders. As a consequence, successful
      treatment is not recognized or decisions towards a less effective second-line therapy are
      made.

      Dual Energy CT (DECT) is a new and robust CT method that allows to exactly quantify the
      intra-tumoral amount of intravenously injected iodinated contrast material PMID 21822784).
      Thus, the technique can be considered as a simple and reliable surrogate of tumor Perfusion
      (PMID 21822784, 21934517, 20498609, 18677487). Initial studies have demonstrated a high
      accuracy of DECT in the differentiation of benign and malignant tumors in the kidney or lung
      (PMID 20498609, 18677487, 18796658). Furthermore, it has been demonstrated that the amount of
      iodine in lung tumors correlates with tumor glucose metabolism (PMID 21822784). These
      findings confirm the results of previous studies that have demonstrated the relationship
      between tumor perfusion, tumor microvessel density and glucose metabolism (PMID 15304661).

      The hypothesis of the study is that DECT is the more accurate diagnostic tool to evaluate
      immediate therapeutic response in patients with GIST undergoing TKI inhibitor therapy (in
      most cases Glivec Â®) than evaluating by RECIST, World Health Organization (WHO) and Choi
      criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival after a three year follow-up</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To visualize and to evaluate therapy response or stable disease of GIST patients undergoing TKI treatment by Dual Energy CT</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastrointestinal Stromal Tumor (GIST)</condition>
  <arm_group>
    <arm_group_label>GIST patients under TKI treatment</arm_group_label>
    <description>GIST patients under TKI treatment are subjected to Dual Energy CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dual Energy CT</intervention_name>
    <description>Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment</description>
    <arm_group_label>GIST patients under TKI treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        gastrointestinal stromal (GIST) patients under tyrosine kinase inhibitor (TKI) treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General inclusion criteria for TKI treatment according to general medical standard
             procedures

        Exclusion Criteria:

          -  General inclusion criteria for TKI treatment according to general medical standard
             procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hohenberger, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical for Surgery, Section SCOTCH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Hohenberger, Prof., MD</last_name>
    <phone>+49621383</phone>
    <phone_ext>2609</phone_ext>
    <email>peter.hohenberger@umm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Center Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Hohenberger, MD</last_name>
      <phone>0049621383</phone>
      <phone_ext>3433</phone_ext>
      <email>studien@gisg.de</email>
    </contact>
    <contact_backup>
      <last_name>Bernd Kasper, MD</last_name>
      <phone>0049621383</phone>
      <phone_ext>3433</phone_ext>
      <email>studien@gisg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Hohenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009 Aug 20;27(24):3969-74. doi: 10.1200/JCO.2008.21.3330. Epub 2009 Jul 20.</citation>
    <PMID>19620483</PMID>
  </reference>
  <reference>
    <citation>Schmid-Bindert G, Henzler T, Chu TQ, Meyer M, Nance JW Jr, Schoepf UJ, Dinter DJ, Apfaltrer P, Krissak R, Manegold C, Schoenberg SO, Fink C. Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT? Eur Radiol. 2012 Jan;22(1):93-103. doi: 10.1007/s00330-011-2230-3. Epub 2011 Aug 7.</citation>
    <PMID>21822784</PMID>
  </reference>
  <reference>
    <citation>Apfaltrer P, Meyer M, Meier C, Henzler T, Barraza JM Jr, Dinter DJ, Hohenberger P, Schoepf UJ, Schoenberg SO, Fink C. Contrast-enhanced dual-energy CT of gastrointestinal stromal tumors: is iodine-related attenuation a potential indicator of tumor response? Invest Radiol. 2012 Jan;47(1):65-70. doi: 10.1097/RLI.0b013e31823003d2.</citation>
    <PMID>21934517</PMID>
  </reference>
  <reference>
    <citation>Graser A, Becker CR, Staehler M, Clevert DA, Macari M, Arndt N, Nikolaou K, Sommer W, Stief C, Reiser MF, Johnson TR. Single-phase dual-energy CT allows for characterization of renal masses as benign or malignant. Invest Radiol. 2010 Jul;45(7):399-405. doi: 10.1097/RLI.0b013e3181e33189.</citation>
    <PMID>20498609</PMID>
  </reference>
  <reference>
    <citation>Graser A, Johnson TR, Chandarana H, Macari M. Dual energy CT: preliminary observations and potential clinical applications in the abdomen. Eur Radiol. 2009 Jan;19(1):13-23. doi: 10.1007/s00330-008-1122-7. Epub 2008 Aug 2. Review.</citation>
    <PMID>18677487</PMID>
  </reference>
  <reference>
    <citation>Chae EJ, Song JW, Seo JB, Krauss B, Jang YM, Song KS. Clinical utility of dual-energy CT in the evaluation of solitary pulmonary nodules: initial experience. Radiology. 2008 Nov;249(2):671-81. doi: 10.1148/radiol.2492071956. Epub 2008 Sep 16.</citation>
    <PMID>18796658</PMID>
  </reference>
  <reference>
    <citation>Yi CA, Lee KS, Kim EA, Han J, Kim H, Kwon OJ, Jeong YJ, Kim S. Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology. 2004 Oct;233(1):191-9. Epub 2004 Aug 10.</citation>
    <PMID>15304661</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Peter Hohenberger</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Gastrointestinal Stromal Tumor (GIST)</keyword>
  <keyword>Dual Energy CT</keyword>
  <keyword>Tyrosine Kinase Inhibitor (TKI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

